Castle Biosciences Inc Revenue Growth Rates (CSTL), Current and Historic Growth - CSIMarket
CSIMarket Company Name, Ticker, Suppliers, else..
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Sales Y/Y Annual
Castle Biosciences Inc   (NASDAQ: CSTL)
    Sector • Healthcare    Industry • Medical Laboratories
   Industry • Medical Laboratories
   Sector • Healthcare
 

CSTL's Revenue Growth by Quarter and Year

Castle Biosciences Inc 's Revenue results by quarter and year



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

API endpoints for this dataset

https://api.csimarket.com/api/v1/companies/CSTL/growth
https://api.csimarket.com/api/v1/companies/CSTL/fundamentals
https://api.csimarket.com/api/v1/companies/CSTL/fundamentals?mode=as_of&as_of=YYYY-MM-DD
Programmatic access for models, analytics, and integration workflows.
Explore the Financial Data API
Financial API Point-in-Time Financial Fundamentals API API Server API Docs API Discovery
Connect Your AI Assistant
How to Connect Your AI Assistant to CSIMarket MCP MCP Server
Access this full dataset via API
Free sample Full docs All endpoints
CSTL Revenue (in millions $) FY 2026 FY 2025 FY 2024 FY 2023
4th Quarter December -
3rd Quarter September 102.89
2nd Quarter June 103.55
1st Quarter March 83.68
FY 290.12

CSTLs Annual Revenue
Castle Biosciences Inc 's Revenue in the fiscal year 2025 $ 344.23 millions
Castle Biosciences Inc 's Revenue in the fiscal year 2024 $ 332.07 millions
Castle Biosciences Inc 's Revenue in the fiscal year 2023 $ 219.79 millions
Castle Biosciences Inc 's Revenue in the fiscal year 2022 $ 137.04 millions
Castle Biosciences Inc 's Revenue in the fiscal year 2021 $ 94.09 millions




CSTL Revenue third quarter 2026 Y/Y Growth Comment
Castle Biosciences Inc reported Revenue improvement of 23.91% year on year in the third quarter 2026, to $ 102.89 millions, this is lower than Castle Biosciences Inc 's recent average Revenue rise of 45.55%.

Looking into third quarter 2026 results within Medical Laboratories industry 24 other companies have achieved higher Revenue growth. While Castle Biosciences Inc ' s Revenue rise of 23.91% ranks overall at the positon no. 2640 in the third quarter 2026.


CSTL Revenue ( Y/Y Growth %) 2026
 FY 2025 FY 2024 FY 2023
4th Quarter December -
3rd Quarter September 23.91 %
2nd Quarter June 20.14 %
1st Quarter March -4.9 %
FY   -

Financial Statements
Castle Biosciences Inc 's third quarter 2026 Revenue $ 102.89 millions CSTL's Income Statement
Castle Biosciences Inc 's third quarter 2025 Revenue $ 83.04 millions Quarterly CSTL's Income Statement


CSTL Revenue (Quarter on Quarter Growth %)

 2026
 FY 2025 FY 2024 FY 2023
4th Quarter December -
3rd Quarter September -0.64 %
2nd Quarter June 23.75 %
1st Quarter March -3.83 %
FY (Year on Year)   -


Back to CSTL Growth rate Comparisons >> Back to CSTL Growth rate Comparisons >>


Revenue third quarter 2026 Y/Y Growth Company Ranking
Within: No.
Medical Laboratories Industry #25
Healthcare Sector #379
Overall #2640

Revenue Y/Y Growth Statistics
High Average Low
127.62 % 45.55 % -2.06 %
(Dec 31 2019)   (Mar 31 2026)
Revenue third quarter 2026 Y/Y Growth Company Ranking
Within: No.
Medical Laboratories Industry #25
Healthcare Sector #379
Overall #2640
Revenue Y/Y Growth Statistics
High Average Low
127.62 % 45.55 % -2.06 %
(Dec 31 2019)   (Mar 31 2026)

Revenue by Quarter for the Fiscal Years 2023, 2024, 2025, 2026

Castle Biosciences Inc 's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
208.08 % 14.2 % -27 %
(Dec 31 2018)  


CSTL's III. Quarter Q/Q Revenue Comment
In the III. Quarter 2026 Castle Biosciences Inc disclosed decrease in Revenue from the second quarter by -0.64% to $ 102.89 millions, from $ 103.55 millions achived in the previous reporting period.

But that's not important problem, as Castle Biosciences Inc 's Revenue generally seem to plunge in this quarter.

Within Medical Laboratories industry 3 other companies have achieved higher Revenue quarter on quarter growth. While Castle Biosciences Inc 's Revenue growth quarter on quarter, overall rank is 447.


Revenue Q/Q Growth Company Ranking
Within: No.
Medical Laboratories Industry #4
Healthcare Sector #95
Overall #447
Revenue Q/Q Growth Company Ranking
Within: No.
Medical Laboratories Industry #4
Healthcare Sector #95
Overall #447
Revenue Q/Q Growth Statistics
High Average Low
208.08 % 14.2 % -27 %
(Dec 31 2018)  


CSTL's III. Quarter Q/Q Revenue Comment
In the III. Quarter 2026 Castle Biosciences Inc disclosed decrease in Revenue from the second quarter by -0.64% to $ 102.89 millions, from $ 103.55 millions achived in the previous reporting period.

But that's not important problem, as Castle Biosciences Inc 's Revenue generally seem to plunge in this quarter.

Within Medical Laboratories industry 3 other companies have achieved higher Revenue quarter on quarter growth. While Castle Biosciences Inc 's Revenue growth quarter on quarter, overall rank is 447.


Castle Biosciences Inc 's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Jun 30 2026)		 12 Months Ending (Mar 31 2026) 12 Months Ending (Dec 31 2025) 12 Months Ending (Sep 30 2025) 12 Months Ending (Jun 30 2025)
Cumulative Revenue 12 Months Ending $ 357.28
Y / Y Revenue Growth (TTM) 3.18 %
Year on Year Revenue Growth Overall Ranking # 851
Seqeuential Revenue Change (TTM) 5.11 %
Seq. Revenue Growth (TTM) Overall Ranking # 2655


Cumulative Revenue growth Comment
Although Castle Biosciences Inc 's Annual Revenue growth year on year were below company's average 45.55% , Revenue announced in the Jun 30 2026 period, show improvement in Revenue trend, to cumulative trailing twelve month growth of 3.18% year on year, from -2.06% in Mar 31 2026.

In the Healthcare sector 174 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 341 to 851.

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Medical Laboratories Industry # 25
Healthcare Sector # 175
Overall # 851

Revenue TTM Y/Y Growth Statistics
High Average Low
127.62 %
 45.55 %
-2.06 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 25
Sector # 379
S&P 500 # 2655
Cumulative Revenue growth Comment
Although Castle Biosciences Inc 's Annual Revenue growth year on year were below company's average 45.55% , Revenue announced in the Jun 30 2026 period, show improvement in Revenue trend, to cumulative trailing twelve month growth of 3.18% year on year, from -2.06% in Mar 31 2026.

In the Healthcare sector 174 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 341 to 851.


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Medical Laboratories Industry # 25
Healthcare Sector # 175
Overall # 851

Revenue TTM Y/Y Growth Statistics
High Average Low
127.62 %
45.55 %
-2.06 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 25
Sector # 379
S&P 500 # 2655




Other Revenue Growth
Medical Laboratories Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
CSTL's Revenue Growth Ratio versus Medical Laboratories Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth




Companies with similar Revenue decrease for the quarter ending Sep 30 2026 within Healthcare SectorY/Y Change %Revenue for the quarter ending Sep 30 2026
Neurocrine Biosciences Inc 41.24%$ 41.238 millions
Transmedics Group Inc 41.15%$ 41.149 millions
Uniqure N v 40.39%$ 40.394 millions
Harrow Inc 40.00%$ 40.001 millions
Mirum Pharmaceuticals Inc 39.63%$ 39.629 millions
Caredx Inc 39.29%$ 39.285 millions
Halozyme Therapeutics Inc 39.15%$ 39.154 millions
Eli Lilly And Company38.61%$ 38.613 millions
Myomo Inc 37.42%$ 37.416 millions
Editas Medicine Inc 37.41%$ 37.412 millions
Beyond Air Inc 36.55%$ 36.545 millions
Clearpoint Neuro Inc 36.27%$ 36.271 millions
Regeneron Pharmaceuticals Inc 36.27%$ 36.265 millions
Travere Therapeutics Inc 36.22%$ 36.215 millions
Omada Health Inc 36.13%$ 36.133 millions
Guardant Health Inc 36.12%$ 36.116 millions
Natera Inc 34.08%$ 34.077 millions
Establishment Labs Holdings Inc 34.08%$ 34.075 millions
Beone Medicines Ltd 33.86%$ 33.861 millions
Ceribell Inc 33.72%$ 33.721 millions
Zomedica Corp 33.12%$ 33.123 millions
Intuitive Surgical Inc 32.71%$ 32.714 millions
Adc Therapeutics Sa32.20%$ 32.197 millions
Biomarin Pharmaceutical Inc32.02%$ 32.019 millions
The Pennant Group Inc 31.96%$ 31.965 millions
Beta Bionics Inc 30.92%$ 30.923 millions
Cadre Holdings inc 30.36%$ 30.362 millions
Krystal Biotech Inc 30.21%$ 30.206 millions
Sight Sciences Inc 29.83%$ 29.828 millions
Biofrontera Inc 29.79%$ 29.794 millions


About Castle Biosciences Inc Revenue Growth Rates (CSTL), Current and Historic Growth - CSIMarket Analysis

How we calculate this

This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years). Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.

What’s included here

Company: Castle Biosciences Inc (CIK 1447362).

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings → XBRL parse → normalization CSIMarket.com Database → growth calculations.
  • Accession: 0001628280-26-071038
  • Figures are derived from filed reports and may be restated; numbers are subject to revision.

Sources: Castle Biosciences Inc’s SEC filings (XBRL/Inline XBRL) and CSIMarket.com’s normalization & QA processes.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.